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1 Abstract 
 
Cancer is a disease driven by genetic as well as by epigenetic changes. 
Epigenetic changes include aberrant histone modifications, global DNA 
hypomethylation and hypermethylation at CpG islands in promoter sites or the 
deregulation and mutation of genes involved in epigenetic mechanisms. The 
aim of our study was to analyse epigenetic changes specific to either hormone 
sensitive or insensitive prostate cancers in order to distinguish prostate cancer 
stages based on epigenetic patterns. Moreover, we intended to define 
differences between prostate cancer characteristics to discover possible tumour 
associated biomarkers.  
We applied several methods in the hormone sensitive LNCaP and the hormone 
insensitive LNCaP-abl, PC-3 and DU145 human prostate cancer cell lines as 
well as tissue samples of human prostate cancers with differences in hormone 
response and/or therapy. Western blot analyses revealed an increased level of 
EZH2 protein in LNCaP and LNCaP-abl cells compared to the androgen 
independent PC-3 and DU145 cells and also detected a reduced level of 
DNMT1.  
Additionally, COBRA analysis displayed a higher methylation pattern of PC-3 
cells compared to the LNCaP and LNCaP-abl cell lines. Further, DNA 
methylation analysis in patient samples exhibited elevated hypermethylation at 
EDNRß, GSTP1 and WNT2 promoter regions in hormone insensitive patient 
samples (HI) compared to cancer tissues of patients with or without hormone 
ablation therapy (naive and HAT patients). Finally, IHC staining showed 
elevated BMI-1, DNMT1 and DNMT3a levels in HI patients compared to naive 
and HAT patients. Our results indicate differences in epigenetic patterns 
between hormone sensitive and insensitive prostate tumours and it will be 
interesting to expand our analyses to genome-wide screens on defined patient 
cohorts.  
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2 Zusammenfassung 
 
Krebs ist eine Erkrankung, die sowohl von genetischen als auch von 
epigenetischen Veränderungen vorangetrieben wird. Zu diesen epigenetischen 
Veränderungen zählen sowohl Abweichungen der Histonmodifikationen, 
Veränderungen der DNA Methylierung in so genannten „CpG islands“  wie auch 
unterschiedliche Regulationen von Genen im epigenetischen Netzwerk der 
Zelle.  
Ziel unserer Arbeit war es epigenetische Veränderungen zwischen Hormon-
sensitiven und Hormon-insensitiven Prostatakrebsarten zu finden, welche es 
ermöglichen Unterschiede innerhalb verschiedener Prostatakrebsstadien 
aufzudecken und somit mögliche  tumorassoziierte Biomarker zu definieren. 
Untersucht wurden die Hormon-abhängigen Zelllinien LNCaP und die Hormon-
unabhängigen Zelllinien LNCaP-abl, PC-3 und DU145 sowie humanes Gewebe 
aus Hormon-sensitiven und -insensitiven Prostatakarzinomen und aus 
Prostatakarzinomen nach Hormonablationstherapie. 
Die in  dieser Studie durchgeführten Proteinanalysen konnten ein erhöhtes 
Level an EZH2 in den beiden verwandten Zelllinien LNCaP und LNCaP-abl 
nachweisen, als auch die verminderte Expression des Enzyms DNMT1 im 
Vergleich zu PC-3 und DU145 Zellen detektieren. Außerdem deuten die  
erhaltenen COBRA Analysedaten auf ein erhöhtes Methylierungsmuster in PC-3 
Zellen im Gegensatz zu LNCaP und LNCaP-abl. In einer Mehrheit von Hormon-
unabhängigen Patientenproben waren EDNRß, GSTP1 und WNT2 
hypermethyliert. BMI-1, DNMT1 und DNMT3a wurden mittels 
immunohistologischem Nachweisverfahren verstärkt in Hormon-insensitven 
Patienten nachgewiesen.  
Unsere Ergebnisse deuten darauf hin, dass epigenetische Unterschiede 
zwischen Hormon-abhängigen und unabhängigen Prostatakrebsstadien 
vorliegen und regen dazu an unsere Analysen auf genomweite Screens in 
definierten Patientenkohorten auszuweiten.  
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3 Introduction 
3.1 Epigenetics 
“Epigenetics is the study of mitotically and/or meiotically heritable changes in 
gene function that cannot be explained by changes in DNA sequence” (Russo, 
Martienssen et al. 1996). The term “epigenetics” was introduced for the first 
time by Conrad Waddington, by combining the greek word epi- (above, over) 
and genetic, thereby illustrating the molecular mechanism which translates the 
genetic information into phenotypes. Epigenetic mechanisms are essential in 
many biological processes including gene and microRNA expression, DNA-
protein interactions, suppression of transposable element mobility, cellular 
differentiation, embryogenesis, X-chromosome inactivation, genomic imprinting 
(Portela and Esteller 2010) and the protection against viral genomes 
(Vaissiere, Sawan et al. 2008). 
Epigenetic regulation is accomplished by three main epigenetic mechanisms: 
DNA methylation, post-translational histone modifications and RNA-mediated 
processes (Egger, Liang et al. 2004). DNA methylation is catalysed by DNA 
methyl-transferases (DNMTs), which transfer methyl groups to cytosine 
residues at the C5 position. CpG islands, which are rich in CG content and 
located mainly in promoter regions, are normally kept free from methylation, 
but hypermethylation at these sides can lead to transcriptional gene silencing 
in cancer and to cancer progression (Bird 1986; Egger, Liang et al. 2004). 
Another major epigenetic mechanism relates to post-translational histone 
modifications. In the nucleus, 147 base pairs of DNA are wrapped around core 
histones, which build up nucleosomes. These molecular units contribute to the 
formation of highly structured chromatin. The level of chromatin compaction, 
which is partially regulated by histone modifications, determines the 
accessibility of DNA. The highly conserved amino-terminal tails of the histone 
proteins (mainly H3 and H4) are targets for post-translational modifications, 
such as acetylation, methylation, phosphorylation, ubiquitination, SUMOylation 
and ADPribosylation. These modifications influence transcriptional activation or 
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inactivation of chromatin regions by guiding the emergence of euchromatin 
(“ON state”) or heterochromatin (“OFF state”) (Jenuwein and Allis 2001) and 
consequently set up an environment to facilitate chromatin dynamics in 
conjunction with other remodelling systems. These modifications are dynamic, 
enabling the cell to respond to different requirements during cell cycle and 
development such as DNA replication, repair, recombination and chromosome 
segregation (Russo, Martienssen et al. 1996). 
The variety and the combination of covalent histone modifications on different 
residues of the amino-terminal tails were assumed to produce a so called 
“histone code” (Strahl and Allis 2000; Jenuwein and Allis 2001).  Nevertheless, 
it is controversial, if the proposed histone code is a cause or the consequence 
of the chromatin state (Henikoff and Shilatifard 2011). 
 
3.2 DNA methylation 
Methylation of DNA is established by DNA methyltransferases (DNMTs), which 
catalyse the transfer of methyl groups from S-Adenosylmethionine (SAM) to 
DNA. DNMTs are divided into maintenance (DNMT1) and de novo (DNMT3a and 
DNMT3b) methyltransferases. During replication, DNMT1 copies the hemi-
methylated DNA pattern from the parental DNA strand to a new daughter 
strand. In this way, the DNA methylation pattern is passed to next cell 
generations (Vaissiere, Sawan et al. 2008). On the other hand, the de novo 
methylation at unmethylated CpG sites is accomplished by DNMT3a and 
DNMT3b (Klose and Bird 2006), which are expressed at high levels in 
embryonic stem cells (Newell-Price, Clark et al. 2000), where de novo 
methylation occurs. 
 
3.3 Histone modifications and Polycomb Group Proteins 
Posttranslational histone acetylation, methylation, phosphorylation, 
ubiquitination, SUMOylation and ADP ribosylation are modifications, which are 
established by different enzymes. Histone acetyltransferases are enzymes 
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targeting lysine (K) residues by transferring acetyl groups and thereby opening 
chromatin and leading to transcriptional activation, whereas histone 
deacetylases (HDACs) are removing acetyl groups. Histone methyltransferases 
(HMTs) play an important role in epigenetic modifications by adding methyl 
groups on arginin (R) and lysine (K) residues. Mono-, di- or trimethylation on 
histone H3 and H4 can either lead to gene activation or repression (Lachner 
and Jenuwein 2002). Trimethylation of histone 3 at lysine 4 (H3K4me3) and 
acetylation at histone 3 at lysine 9 (H3K9ac) indicate active DNA (Liang, Lin et 
al. 2004), while in contrast H3K9me3 and H3K27me3 lead to transcriptional 
repression and represent an inactive or silent state of DNA (Fischle, Wang et 
al. 2003). Enhancer of Zeste homologue 2 (EZH2) is the catalytic subunit of 
the polycomb repressive complex 2 (PRC2) and is responsible for H3K27 
trimethylation (Cao, Wang et al. 2002) due to its HMT-activity. The H3K27me3 
serves as a hallmark for the recruitment of additional polycomb group (PcG) 
proteins, for example polycomb repressive complex 1 (PRC1) (Min, Zhang et 
al. 2003), thereby fostering and maintaining the heritable and repressive 
chromatin state and determining cellular memory (Ringrose and Paro 2004). 
Overexpression of or changes within this complex organisation has been 
observed during cancer formation and progression (Kondo, Shen et al. 2008; 
Yang, Karuturi et al. 2009). 
 
3.4 Epigenetics and disease 
Heritable epigenetic changes are detected early during tumour development 
(Nelson, De Marzo et al. 2009) (Baylin and Ohm 2006). Epigenetic changes 
can include the deregulation of HMTs and histone demethylases, the 
overexpression of HDACs and the global loss of histone acetylation, which has 
been observed in several types of cancers (Kelly, De Carvalho et al. 2010). 
Epimutations such as defects in DNA methylation and aberrant histone 
modifications dramatically change the cellular methylation profile and can 
contribute to carcinogenesis through several events, such as repression of 
tumour suppressor genes, activation of normally silent oncogenes, the 
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reactivation of embryonic genes, loss of imprinting, disordered microRNA 
expression, activation of retro-transposons (Nelson, De Marzo et al. 2009) and 
aberrant gene expression in foreign tissues. In general, the cancer genome can 
be characterised by a global loss of methylation (hypomethylation), whereas 
simultaneously a gain of methylation (hypermethylation) at promoter sites 
occurs (Herman and Baylin 2003; Feinberg and Tycko 2004). Hypermethylation 
of tumour suppressor genes is associated with cancer and is correlated to 
transcriptional silencing (Jones and Baylin 2002; Herman and Baylin 2003; 
Cooper and Foster 2008). A very common example for epigenetic gene 
silencing is the CDKN2A gene locus, which encodes the tumour suppressor 
proteins p14 and p16. It has been shown that the repression of the CDKN2A 
locus together with the PcG ring finger oncogene B lymphoma Mo-MLV 
insertion region 1 homolog (BMI-1) harbours oncogenic potential (Itahana, Zou 
et al. 2003) and that epigenetic silencing of CDNK2A occurs in many cancer 
types. The term cross-talk is used to link DNA methylation with chromatin 
modifications. Cross-talk implies that more than just one mechanism can 
contribute to gene silencing and lead to tumour development. For example, it 
was shown by Viré et al that EZH2 is needed for the CpG methylation of target 
promoters, through direct contact with DNMTs (Vire, Brenner et al. 2006). 
Another interesting study demonstrated the decrease of EZH2 and BMI-1 
through inhibition of DNMT1 and DNMT3b. They showed that DNMTs regulate 
p16 expression levels by direct modification of DNA methylation and as well as 
indirect histone modification on the p16 promoter region (So, Jung et al. 
2011).  
 
3.5 Prostate cancer 
Among males, prostate cancer (PC) is the second most frequently diagnosed 
cancer and the sixth leading cause of death in the western world (Jemal, Bray 
et al. 2011). Prostate specific antigen (PSA) screening of serum is used for 
early detection and determination of prostate cancer, although recent studies 
conclude that PSA screening is only useful to verify the presence of benign 
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prostatic hyperplasia, but is not specific for advanced stages of disease 
(Stamey, Caldwell et al. 2004). Observations indicate that this detection 
method is limited in specificity and sensitivity (Yegnasubramanian, Kowalski et 
al. 2004). Nevertheless, still one third of PC patients with elevated PSA levels 
undergo unneeded surgical castration, although they do not suffer from a 
malignant form of cancer (Sidransky 2002). Conventional therapies include 
irradiation and radical prostatectomy. As PC onset and progression are 
promoted by androgens, which operate through the androgen receptor (AR), 
applied treatments are frequently supplemented by androgen deprivation 
therapies in certain cases (Heinlein and Chang 2004). These therapeutic 
strategies can lead to the onset of androgen-independent cancer, that is 
almost exclusively untreatable and is termed as hormone refractory, androgen-
independent or castration-resistant prostate cancer (Shen and Abate-Shen 
2010).  
Pathologically, PC can be classified as adenocarcinoma appearing mostly in the 
peripheral zone of the prostate. Tumours are further classified by Gleason 
scoring (Gleason 1-5) to histopathologically evaluate the grade of malignant 
tissue (Shen and Abate-Shen 2010).  
 
3.6 Epigenetics and prostate cancer 
Prostate carcinogenesis is a multi-step process driven by genetic and 
epigenetic changes (DeMarzo 2007). As PSA screening is very unspecific, the 
aim of many studies in prostate cancer is to find new biomarkers, for instance 
methylation markers (Laird 2003), which can discriminate between different 
stages of disease progression or allow for the detection of an existing disease 
(Laird 1997). One potential tumour marker for PC diagnosis is methylation of 
Glutathione S-transferase P (GSTP1), which is methylated in 90% and a 
potential biomarker in PC cases, but not in normal tissue (Lee, Morton et al. 
1994; Jeronimo, Usadel et al. 2001; Nakayama, Bennett et al. 2003). The 
epigenetic silencing of GSTP1 may promote the vulnerability of prostate tissue 
to oxidative stress (Shen and Abate-Shen 2010), which results in DNA damage 
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and assists cancer initiation (Poulsen 1998). Besides GSTP1, other genes have 
been reported to be hypermethylated, such as adenomatous polyposis coli 
(APC) (Kang, Lee et al. 2004) and Ras association domain-containing protein 1 
(RASSF1alpha) (Lui 2002). Co-occurrence of methylated GSTP1 together with 
APC facilitates a more sensitive detection (Jeronimo, Henrique et al. 2004). 
Also, endothelial receptor type B (EDNRß) methylation showed a strong 
correlation with disease progression in prostate cancer (Bastian, Palapattu et 
al. 2008) as well as down-regulation of estrogen receptor alpha (ESR-1), which 
is also due to promoter methylation and is linked to cancer metastasis (Li et al. 
2004). Interestingly, ESR-1 promoter methylation is rather heterogeneous 
among PC, which may correlate with the tumour stage and/or disease 
progression (Yegnasubramanian, Kowalski et al. 2004; Kwabi-Addo, Chung et 
al. 2007; Vasiljevic, Wu et al. 2011). Aberrantly expressed mediators of the 
epigenetic machinery can also contribute to cancer formation. For example, 
increased expression of DNMTs and EZH2 was found in PC compared to normal 
tissue (Gravina, Marampon et al. 2011) (Varambally, Dhanasekaran et al. 
2002). EZH2 can be seen as a potential oncogene and its over-expression or 
increase during disease progression is linked to elevated H3K27me2 and 
H3K27me3 marks as well as an increase in HDAC1 levels (Varambally, 
Dhanasekaran et al. 2002; Chen 2005; Saramaki, Tammela et al. 2006). Beke 
et al observed that the human prostate cancer cell line PC-3, which does not 
respond to androgens, and the AR positive cell line LNCaP significantly differ in 
H3K27me3 levels. This is correlated with either elevated or reduced PSP94 
expression (Beke, Nuytten et al. 2007). PSP94 is a tumour suppressor protein 
(encoded by the MSMB gene) and its expression is progressively decreased 
during PC development from an early, androgen-dependent to a late androgen-
independent state (Vanaja, Cheville et al. 2003; Stanbrough, Bubley et al. 
2006). However, the Dnmt-1 increase is also an effect of increased proliferation 
(Szyf, Bozovic et al. 1991) as DNMT1 is cell cycle regulated, whereas EZH2 
expression is cell cycle independent (Bracken, Pasini et al. 2003). 
Recent studies suggest that the transition of prostate cancer from hormone 
dependent to hormone-resistant PC phenotypes is dependent on epigenetic 
15 
 
alterations (Gravina, Marampon et al. 2011). Aberrant DNMT1 expression is 
correlated with the occurrence of androgen independence in prostate cancer 
(Chen, Chen et al. 2010), as well as the up-regulation of DNMT3a and DNMT3b 
(Gravina, Marampon et al. 2011). WNT1 expression levels were shown to be 
higher in LNCaP cells compared to PC-3 cells (Thiele, Rauner et al. 2011), 
whereas the RNA expression pattern of patient tissues for WNT2, another gene 
of the WNT signalling pathway, was observed to be down-regulated in prostate 
tumours (Wissmann, Wild et al. 2003). However, it has to be taken into 
account that epigenetic changes are also an phenomenon of ageing, for 
example regarding the down-regulation of ESR-1 (Li, Shiina et al. 2004), which 
increases with patients age. The increase in PC incidences at an older age 
reflects this age-dependent process (Li, Shiina et al. 2004). 
 
3.8 Project outline  
In this study, we investigated whether hormone dependent and independent 
prostate carcinomas display an altered methylation profile at CpG islands in 
promoter regions of candidate tumour suppressor genes and if differences in 
histone modifications and expression of epigenetic enzymes can be seen 
between hormone dependent or independent prostate cancer. In order to 
answer these questions we performed combined bisulfite restriction analysis 
(COBRA), chromatin immunoprecipitation (ChIP), immunohistochemistry 
(IHC), MethylMiner and Western Blot analysis in selected prostate cancer cell 
lines and in patient samples of prostate carcinomas. We used formalin fixed 
paraffin embedded (FFPE) material of prostate cancer tissue to isolate DNA for 
methylation analysis (COBRA). Furthermore, we manufactured a tissue array 
containing the same prostate cancer samples to perform IHC analysis.  
COBRA assay was performed on the three different human prostate cancer cell 
lines LNCaP, LNCaP-abl and PC-3, representing hormone dependent (LNCaP) or 
independent (LNCaP-abl and PC-3) cancer forms. We also analysed patient 
samples belonging to three cancer groups, which differed in therapy treatment 
and androgen response. Particularly, we used eight different patients that were 
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either treated with hormone ablation therapy or untreated (naïve) and seven 
hormone insensitive prostate cancer patients. We performed COBRA assays on 
CpG islands at the promoters of APC, death-associated protein kinase 1 (DAPK-
1), EDNRB, ESR-1, GSTP1, p14, p16, RASSF1 and Wingless-type MMTV 
integration site family member 2 (WNT2).  
Additionally, IHC staining was performed with the same patient samples as 
described above to determine epigenetic and cellular alterations between these 
different PC stages. Altogether, we analysed the status of ten proteins involved 
in epigenetic mechanisms. In this study, the expression status of BMI-1, 
CCCTC-binding factor (CTCF), DNMT1, DNMT3a, EZH2, HDAC1, HDAC2, HDAC3 
as well as the level of H3K4 and H3K27me3 modifications were analysed. Next, 
we investigated histone modification patterns at the promoter site of the proto-
oncogene WNT1, in the two prostate cancer cell lines LNCaP and LNCaP-abl by 
ChIP analysis in order to see if differences between these related cell lines with 
a different androgen response are reflected by histone modifications.  
We applied MethylMiner assay on LNCaP cell lines as a first-line experiment in 
order to perform genome wide DNA methylation analyses in the future. 
Therefore, DAPK-1, SH2 domain-containing protein tyrosine phosphatase 
(SHP2), ubiquitin-conjugating enzyme E2B (UBE2B) and WNT2 were chosen as 
genes of interest. Finally, Western Blot analysis was performed on four human 
PC cell lines (LNCaP, LNCaP-abl, PC-3 and DU145) to evaluate the protein 
levels of EZH2 and DNMT1. 
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4 Material and Methods 
4.1 Media, Solutions and Reagents 
 
Hunt Buffer 
20mM Tris pH 8 
100mM NaCl  
1mM EDTA 
0.5% NP-40  
Protease (Roche - 50xstock - complete)  
Phosphatase Inhibitor (Halt Phosphatase Inhibitor Cocktail - Thermo Scientific) 
in H2O, filtered 
 
RIPA Buffer for Western Blot 
50mM Tris pH 8 
150mM NaCl 
1% NP-40 
0.5% DOC 
0.1% SDS  
Protease and Phosphatase Inhibitor (Roche) 
in dH2O, filtered 
 
SDS Loading Dye 
100mM TrisHCl pH 6.8  
200mM DTT 
4% SDS 
20% Glycerine 
~20mg Bromophenolblue 
 
Electrophoresis Buffer 
14.4g Glycine  
3g Tris  
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1g SDS  
filled up to 1L with dH2O. 
 
Transfer Buffer 
2.5g Tris 
11.2g Glycerine 
200ml Methanol  
filled up to 1L with dH2O. 
 
Ponceau Red solution 
0.5M TBS  
150mM NaCl 
50mM Tris Base) 
in H2O 
 
Blocking Solution 
1xTBS-T (1xTBS 0.5M; 0.1% Tween) 
5% non-fat dry milk powder 
0.02% Na-Azide 
 
10x PBS  
28.8g Sodiumhydrogenphosphate-dihydrate  
5.2g Sodiumdihydrogenphosphate-monohydrate  
90g NaCl adjust to pH 7.2-7.6  
fill up with dH2O to 1L.  
 
10xTBS (0.5 M)  
60.5g Tris-Base  
90g NaCl Adjust with HCl to pH 7.5  
(TBS-T: 0.1% Tween-20)  
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BSA/PBS 
0.5% Bovine Serum Albumin 
1xPBS 
in H2O 
 
TE/EDTA Buffer 
10mM TrisHCl pH 8.1 
1mM Ethylene-diamine-tetraacetic-acid  
in H2O 
 
RIPA Buffer for ChIP Analysis 
50mM Hepes-KOH pH 7.6 
1mM NP-40 
0.7% Na-Desoxycholate 
500mM LiCl 
Protease Inhibitor (Roche) 
in dH2O, filtered 
 
Cell lysis buffer (DNA extraction) 
0.5M NaCl 
0.2% SDS 
0.1M Tris pH 8.3 
5mM EDTA 
in H2O, filtered 
 
ChIP Dilution Buffer 
0.01% SDS 
1.1% Triton X-100 
1.2mM EDTA 
16.7mM TrisHCl pH 8.1 
167mM NaCl 
Protease Inhibitor (Roche)  
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in H2O, filtered 
 
SDS-Lysis-Buffer (ChIP) 
1% SDS 
10mM EDTA 
50mM Tris pH 8.1 
Protease Inhibitor (Roche) 
in H2O, filtered 
 
Cell Lysis Buffer 1 (ChIP) 
50mM Hepes-KOH pH 7.5  
140mM NaCl 
1mM EDTA 
10% glycerol 
0.5% NP-40 
0.25% Triton X-100 
Protease Inhibitor (Roche) 
in H2O, filtered 
 
Cell Lysis Buffer 2 (ChIP) 
10mM TrisHCl pH 8 
200mM NaCl 
1mM EDTA 
0.5mM EGTA 
Protease Inhibitor (Roche) 
in H2O, filtered 
 
Elution Buffer (ChIP) 
1% SDS 
0.1M NaHCO3 
prepared fresh on the same day 
in dH2O, filtered 
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12% Polyacrylamid Gel 
12% PAA 
1xTBE 
1% APS 
TEMED 
in H2O 
 
4.2 Antibodies 
4.2.1 Primary Antibodies for Western Blot Analysis 
 ß-actin (Cell Signalling 4967S, rabbit) – 1:1000 dilution in blocking 
solution – 45kDa  
 Dnmt1 (santa cruz sc-10222, goat polyclonal) – 1:1000 dilution in 
blocking solution – 183kDa  
 EZH2 (Sigma E7031, rabbit polyclonal) - 1:1000 dilution in blocking 
solution –100kDa 
4.2.2 Secondary Antibodies for Western Blot Analysis 
 Polyclonal rabbit anti-mouse IgG (HRP) (DakoCytomation, R0270) – 
1:10000 dilution in TBS-T  
 Fox F(ab’)2-fragment goat anti rabbit IgG (Invitrogen, L43000) – 
1:10000 dilution in TBS-T  
4.2.3  Antibodies for IHC staining 
HDAC1 (Seiser laboratory - mouse)  
HDAC2 (Seiser laboratory - mouse) 
HDAC3 (Cell Signaling; #2632) 
BMI-1 (Millipore; # 05-637)  
CTCF (Cell Signaling; # 3418) 
DNMT1 (abcam; # ab13537)  
DNMT3a (santa cruz; # sc-20703) 
EZH2 (sigma; # E6906)  
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H3K4me3 (abcam; # ab8580)  
H3K27me3 (abcam; # ab6002) 
Ki67 (Novocastra; # NCL-KI67-P) 
 
4.3 Cell lines and cell culture 
We used the human prostate cancer cell lines PC-3, LNCaP clone FGC (CRL-
1740™) and the LNCaP subline LNCaP-abl. Cell lines were obtained from ATCC 
and were grown in RPMI 1640 medium (GIBCO) containing 10% fetal bovine 
serum (FBS) and 1% penicillin/streptomycin at 37°C in an atmosphere of 5% 
CO2 and 95% room air. LNCaP and LNCaP abl cells were seeded and grown in 
cell culture dishes (greiner bio-one CELLSTAR; 145x20mm) until the plates 
were mostly overgrown and reached an adequate amount of cells. 
4.3.1 Cell line description 
In our study we used the prostate cancer cell lines PC-3, LNCaP and the LNCaP 
subline LNCaP-abl as well as DU145. PC-3 is a human prostate carcinoma cell 
line that was established from a bone marrow metastasis grade IV prostate 
cancer after androgen suppression therapy. Although PC-3 cells express the 
androgen receptor (AR), the cell line is androgen independent. LNCaP cells are 
derived from non-metastatic lymph nodes and are a slow growing, androgen 
dependent cell line, expressing the androgen receptor (AR). Their proliferation 
is regulated by androgens in a biphasic manner, which means that growth is 
enhanced by low concentrations of dihydrotestosterone (DHT – a metabolite of 
testosterone), whereas higher androgen levels reduce cell proliferation (Lee, 
Sutkowski et al. 1995). The new subline LNCaP-abl was established by Culig et 
al. after long-term androgen ablation of LNCaP cells (passages >75). LNCaP-
abl cells are an androgen-independent (hormone insensitive - HI) cell line. 
Their proliferation is stimulated by bicalutamide, a non-steroidal anti-
androgen, which leads to an increase in AR expression. This cell line has 
adapted to an androgen-depleted environment by generating a hyper-reactive 
AR (Culig, Hoffmann et al. 1999). In contrast, androgens have an inhibitory 
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effect on cell growth and proliferation in LNCaP-abl. For this reason, the 
LNCaP-abl cell line is a useful model system for studying therapy-resistant 
prostate cancer (androgen deprivation), whereas LNCaP represent an androgen 
dependent PC at an early tumour stage. 
 
4.4 Tissue Array of prostate cancer patient samples 
Three different cohorts of prostate cancer patients were analysed. The first 
cohort included patients undergoing radical prostatectomys followed by 
androgen deprivation therapy (n=8), the second cohort patients undergoing 
radical prostatectomys (n=8) and the third cohort patients include hormone 
insensitive tumours (n=7). As control, non-malignant tissue samples were 
used from patients undergoing cystectomy (n=1) serving as control. Formalin 
fixed paraffin embedded (FFPE) tumours from prostate cancer patients were 
provided by the Institute of Clinical Pathology at the Medical University of 
Vienna. 
A tissue array was prepared by using a small paraffin block which served as an 
acceptor block. Patient tissues of interest were cut out from donor blocks and 
transferred to the acceptor block (Genxpress). The order of patient samples is 
shown in Supp.Figure3.  
 
4.5 Immunohistochemistry – IHC 
IHC is a method of detecting the presence of antigens in cells or tissue sections 
by utilization the specific binding of an antibody to its antigen. The antibody-
antigen interaction is visualized by coupling the enzyme peroxidase to the 
antibody, which catalyse a colour-producing reaction. 
4.5.1 IHC Protocol 
Several sections of paraffin embedded tissues were sliced (about 4µm) using a 
microtome and mounted on slides. For deparaffinization, the slides were 
incubated over night (o/n) at 57°C, followed by washing and incubation steps 
with xylol, different dilutions (96%, 70% and 50%) of ethanol (EtOH) and 
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aqua dest (dAQ). For antigen retrieval citrate buffer (DAKO; pH6) was used 
followed by either microwave heating or heating by autoclave at 121°C. After 
heating, the slides had to cool down to room temperature and were washed 
with 1xPBS (pH 7.2 – pH 7.6). The tissue was blocked with H2O2 (GATT-
KOLLER), avidin and biotin (Zamponi Diagnostik) for 10 min each at room 
temperature (RT) and in between washed with 1xPBS. Slides were blocked 7 
min with Super Block (Zamponi Diagnostik), washed with 1xPBS, incubated 
with the diluted antibodies (diluted in 1% PBS/BSA) (see table) and incubated 
o/n at 4°C. After incubation the slides were washed with 1xPBS and incubated 
with the secondary antibody (anti-polyvalent biotinylated antibody) (Zamponi 
Diagnostik) for 10 min at RT and then washed three times with 1x PBS, 
followed by a final incubation with strepavidin horse radish peroxidase (HRP) 
for 10min and a final washing step with 1xPBS. AEC staining (3-amino-9-
ethylcarbazole) (ID-Labs) was used for AB detection. Slides were counter 
stained with haemalaun solution (Merck) for 30 sec, washed with aqua dest. 
and mounted with aquatex (Merck) (Table 1). 
 
Primary Antibody  Dilution Buffer Conditions  
BMI-1  (Millipore) 1:100 Citrate Autoclave 
CTCF (Cell Signalling) 1:250 Citrate Autoclave 
DNMT1 (abcam) 1:100 Citrate Autoclave 
DNMT3a (santa cruz) 1:200 Citrate Autoclave 
EZH2 (active motif) 1:300 Citrate Autoclave  
HDAC1 (Seiser laboratory) 1:100 Citrate Microwave 
HDAC2 (Seiser laboratory) 1:100 Citrate Microwave 
HDAC3 (Cell Signalling) 1:100 Citrate Autoclave 
H3K27me3 (abcam) 1:400 Citrate Autoclave 
H3K4me3 (abcam) 1:100 Citrate Autoclave 
Ki67 (Novocastra, NCL-KI67P) 1:1000 Citrate Autoclave 
Table 1| Overview of antibodies and dilutions for IHC staining. 
 
4.6 Combined Bisulfite Restriction Analysis – COBRA 
For determination of the methylation status of prostate cancer patients and in 
human prostate cancer cell lines we performed COBRA assay. This method is 
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used to distinguish methylated CpG sites from unmethylated sites by treating 
genomic DNA with sodium bisulfite. Bisulite treatment converts unmethylated 
cytosines in the DNA sequence into uracils, whereas methylated cytosins 
remain unchanged. In the subsequent PCR the resulting uracils are amplified 
as thymines that allow the discrimination between originally methylated and 
unmethylated Cs by restriction enzymes, which have a CG in their recognition 
sequence and are thus cutting only initially methylated and unconverted CGs.  
4.6.1 DNA Isolation of FFPE tissue samples 
2-3 pieces of formalin fixed paraffin embedded (FFPE) patient tumour tissue 
samples were cut out with a tissue arrayer punch (Genxpress) and transferred 
into a 1.5mL Eppendorf tube. To remove the paraffin from tissues, 1000µL 
Xylol (Merck) were added. Compounds were mixed by inverting the tube. 
Centrifugation at full speed for 2 min was performed and the resulting 
supernatant was discarded. In addition, 800µL Xylol and 400µL EtOH (Merck) 
absolute were added and mixed by inverting the tube. Centrifugation at full 
speed for 2 min was performed and the resulting supernatant was discarded. 
Finally, the pellet was washed with 1000µL EtOH and dried at 55°C. 180µL ATL 
Puffer and 20µL Proteinase K (QIAamp DNA Mini Kit) were added to each pellet 
and incubated at 56°C on the thermomixer for 64 hours. Further steps for DNA 
purification were carried out according to QIAamp DNA Mini Kit protocol. In the 
final two steps of the QIAamp DNA Mini Kit the recommended amount of 
distilled water for elution was increased to 50µL. The DNA amount was 
measured with NanoDrop 2000 (Thermo Scientific).  
4.6.2 DNA Isolation from cell lines 
Cells were pelleted by centrifugation 5 min at 1500rpm and washed with 1x 
PBS. The cell pellet was then dissolved in 500-1000µL cell lysis buffer. 20µg/ml 
RNAseA were added and the cell lysate was incubated at 37°C for 30-60 min. 
500µg/ml Proteinase K (10mg/mL) was added and incubated o/n at 55°C. 
After o/n incubation, a Phenol/Chloroform DNA extraction was performed using 
phase lock gel tubes (5prime). The DNA containing phase was taken off and 
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one volume of isopropanol (Merck) was added. The solution was mixed by 
inverting the tube and DNA was pelleted by centrifugation at full speed at 4°C 
for 10 min. Subsequently the DNA pellet was washed once with one volume 
75% EtOH; dried at RT and dissolved in 100-500µL dH2O at 37°C until well 
dissolved. DNA concentration was measured with the NanoDrop 
spectrophotometer (Thermo Scientific). 
4.6.3 COBRA Protocol 
After DNA Isolation, 1µg DNA of the patient samples was bisulfite converted 
according to EZ DNA MethylationTM Kit (Zymo Research). 16 cycles (95°C for 
30 sec, 50°C for 60 min) were performed o/n in a thermocycler. The bisulite 
converted DNA was eluted in 30µL - 50µL dH2O and stored at -20°C for further 
analysis. The bisulfite-converted DNA was amplified by PCR with methylation 
insensitive primers (Table 2). Primers for amplification of bisulfite converted 
DNA were designed using the SEQUENOM EpiDesigner program 
(www.epidesigner.com). DNA amplification was checked on a 1.5% agarose gel 
with 5µL of the PCR product. As positive control, DNA of peripheral blood 
mono-nuclear cells (PBMCs) was treated with SssI enzyme resulting in fully 
100% methylated DNA (see below; SssI treatment). Untreated PBMC DNA 
served as unmethylated negative control. In the course of the experimental 
setup, two different PCR settings were performed, which differ in the 
application of used reagents. Either the JumpStart REDTaq DNA Polymerase 
Master Mix (Sigma-Aldrich) or AmpliTaq Gold 360 (Applied Biosynthesis) 
system was used. 
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Table 2| COBRA PCR.  
 
PCR reaction setup 1: 
16.375µL dH2O 
5µL MgCl2 
2.5µL Buffer 
2µL DNA sample 
1µL Primer fw/rev (0.5µL each) 
0.5µL dNTPs 
0.125µL AmpliTaq Gold 360 (Applied 
Biosynthesis) 
PCR reaction setup 2: 
10µL of JumpStart REDTaq DNA 
Polymerase (Sigma-Aldrich) 
7µL dH2O 
2µL DNA sample 
1µL primer fw/rev (0.5µL each)
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RestrictionEnzyme BstUI (NEB) HhaI (NEB) HhaI 
(Fermentas) 
TaqaI (NEB) 
Sequence 5'...CG|CG...3' 
3'...GC|GC...5' 
5'...GCG|C...3' 
3'...C|GCG...5' 
5'...GCG|C...3' 
3'...C|GCG...5' 
5'...T|CGA...3' 
3'...AGC|T...5' 
Buffer  
amount  
10xBuffer 
2µL 
10xBuffer 
2µL 
10xTango Buffer 
2µL 
10xBuffer 
2µL 
Temperature °C 60 37 37 65 
Enzyme  0.25µL 0.25µL 0.5µL 0.25µL 
Incubation time  
for  digestion 
3 hours 3 hours 3 hours 3 hours 
dH2O 2.75µL 2.75µL 2.5µL 2.75µL 
PCR Product 15µL 15µL 15µL 15µL 
Table 3| COBRA Restriction: Reaction-Setup for restriction digestion of PCR products.  
 
 
The restriction of the PCR products was performed under appropriate 
conditions (Table 3) in a thermocycler.  After restriction the sample was loaded 
onto a 12% polyacrylamid gel together with 1µL DNA-loading dye. Restriction 
fragments were separated and visualized by Midori Green (genxpress) staining. 
4.6.4 SssI Treatment 
For COBRA fully methylated DNA was generated by treating bisulfite converted 
PBMC DNA with the bacterial CpG Methyltransferase M.SssI. For this purpose, 
30µg genomic DNA was used and 40µL 10xNEB2 buffer, 2µL S-Adenosyl 
methionine (SAM) and 5µL M.SssI (NEB - CpG methylatransferase) was added 
and filled up to a total volume of 400µL with dH2O. After 4 hours at 37°C the 
reaction was boosted by adding another 1µL SAM, 2µL M.SssI and 47µL dH2O 
and incubated o/n under the same conditions. DNA was then purified either 
with Qiaquick Gel Extraction Kit (Gel Extraction Kit Protocol; Handbook 
11/2006 page 25) or by DNA precipitation. For DNA precipitation, NaCl in a 
final concentration of 400mM, two volumes of 96% EtOH and 1µL glycogen 
were added to the M.SssI treated DNA sample and incubated one hour at 
minus 80°C. After centrifugation at full speed, 300µL of 70% EtOH was added 
to the sample and centrifuged again at full speed. The supernatant was 
discarded and the pellet was dissolved in 100µL TE buffer (10mM TrisHCl pH 
8.1; 1mM EDTA). M.SssI treated DNA was stored at 4°C for further 
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experiments. Bisulfite converted PBMC DNA was used as unmethylated control, 
whereas SssI treated PBMC DNA served as methylated control.  
 
4.7 Chromatin Immunoprecipitation – ChIP 
Chromatin immunoprecipitation (ChIP) is used to investigate the interaction 
between proteins and DNA. It is also a major assay to analyse histone 
modifications, in which a histone modification specific antibody is used to 
precipitate cross-linked chromatin. Purified DNA can be analyzed afterwards by 
real time PCR.  
4.7.1 ChIP Protocol 
Using ChIP analysis, LnCaP and LnCaP-abl cell lines were cultured as described 
previously (2.3). The first step was to cross-link proteins to chromatin. 
Therefore, formaldehyde (Thermo Scientific ampoules) in an end-concentration 
of 1% per dish was added to the cultured cells in medium. The cells were then 
incubated shaking for 15 min at RT. To quench the reaction, 1/10 volume of 
1.25M glycine (Bio-Rad) was added to cells and dishes were incubated shaking 
for 5 min at RT. Then the cells were washed with ice cold PBS. Adherent cells 
were scraped off, with a silicon cell scraper (Costar) together with ice cold PBS 
+ phosphatase inhibitor (pH 7.2 – pH 7.6). The harvested cells were pooled in 
a 50mL tube (Greiner) and centrifuged at 2000 -2200rpm at 4°C for 5 min. 
Supernatant was discarded and the cell pellet was gently suspended in another 
5mL ice cold PBS + PI and pelleted by centrifugation (2000rpm). The 
supernatant was discarded and the cell pellet was resuspended in 5mL of cell 
lysis buffer 1 + PI. The suspension was incubated on a rotating wheel at 4°C 
for 10 min, followed by centrifugation at 2000 – 2200rpm at 4°C for 5 min. 
The supernatant was taken off and in the next step 5mL of Lysis Buffer 2 + PI 
were added and incubated for 10 min at RT. The resulting cell pellet was 
resuspended in an adequate amount (depending on the cell pellet size) ranging 
between 200-1000µL in SDS-Lysis-Buffer + PI. The cell suspension was 
sonicated between 20-30 times (INVITROGEN Sonicator). Every 5 times the 
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water temperature was checked according to the heat development 
(temperature should not raise over 10°C). To determine the length of the 
chromatin, a 20µL aliquot was taken from the sonicated cells. 80µL dH2O and 
10µL 5M NaCl was added to the aliquote and boiled for 15 min at 95°C. 
Subsequently, 1µL RNAase (DNAse free) (Invitrogen) was added and incubated 
30min at 37°C. Afterwards, 1µL Proteinase K (10mg/mL) (Invitrogen) was 
added and incubated another 30 min at 45°C. The DNA was purified with 
QIAquick PCR purification kit (QIAquick PCR Purification Microcentrifuge and 
Vacuum Protocol) and eluted in 30µL dH2O. Finally, the DNA concentration was 
measured with NanoDrop 2000 (Thermo Scientific) and the remaining DNA was 
checked on a 2% agarose gel (500 and 1000 basepairs). For precipitation, 
100µg chromatin, 10µg antibody (EZH2 active motif 39875/39876; H3K27 
millipore cat.07-449) and 50-100µL Invitrogen Dynabeads Protein G 
(cat.100.03D; 100.04D) were used. Before incubation with the antibody, the 
chromatin was filled up with SDS Lysis Buffer (e.g. to 100µL) and was diluted 
to an end-concentration of 1x with ChIP Dilution Buffer + PI. As input control, 
1% chromatin was taken away and stored at -20°C. Incubation of chromatin 
with the antibody was performed on a rotating wheel at 4°C for one hour.  IgG 
beads were washed with 1mL BSA/PBS (0.5% BSA; 1xPBS) three times using a 
magnetic rack. After incubation of the antibody with the chromatin, the beads 
were added and incubated o/n at 4°C on a rotating wheel. As a control, 
chromatin of each cell line was also incubated with beads but without antibody. 
After incubation, the beads were washed 5 times with 1mL RIPA Buffer + PI 
using a magnetic rack and two times with TE Buffer. Chromatin DNA was eluted 
by incubating the beads two times with 200µL elution buffer for 15 min on a 
rotating wheel at RT. Chromatin input was filled up to a final volume of 400µL 
with elution buffer. For reverse cross-linking, 16µL 5M NaCl were added to the 
chromatin input and the precipitated chromatin was incubated 4 hours at 65°C. 
In addition 8µL 0.5M EDTA, 16µL 1M TrisHCl pH 6.5 and 2µL 10mg/mL 
proteinase K (Invitrogen) were added and  incubated o/n at 55°C. For DNA 
isolation, a Phenol/Chloroform (25 Phenol: 24Chloroform: 1Isoamylalcohol) 
extraction was performed after incubation by the use of phase lock tubes 
31 
 
(5prime). Therefore, two volumes (800µL) EtOH, 80µL 3M NaOAc and 1µL 
glycogen were added to the DNA extract and incubated at -80°C for one hour. 
Then the sample was centrifugated at full speed at 4°C, the supernatant was 
taken off and the DNA pellet was washed with 70% EtOH once. The 
precipitated DNA was dried and dissolved in 100µL dH2O for further analysis 
with real-time PCR using site specific primers. Quantitative real-time PCR was 
performed with FASTAKapa Mastermix (Peqlab Biotechnologies) on a Biorad 
cycler. For PCR reaction 10µL Mastermix, 7µL dH2O, 2µl of cDNA and 1µL 
primer (fw + rev) were used in each run. Glyceraldehyde-3phosphate 
dehydrogenase (GAPDH) was used as control region. 
 
Primer Sequences 
WNT1_fw: 5'-CCA GGG TTG TTA AAG CCA GA-3' and rv: 5'-AGC AGC AGC GTA 
GAA AC-3' 
MYT1pd_fw: 5'-AGG CAC CTT CTG TTG GCC GA-3' and rv: 5'-AGG CAG CTG 
CCT CCC GTA CA-3'    
MYT1prox_fw: 5'-GGA CAC TGT GCG GAA GAG TT-3' and rv: 5'-TTG TCT GCT 
TTT CTG CAA TC-3' 
GAPDH fw: 5’-GGT GGT CTC CTC TGA CTT CAA CA-3’ and rv: 5’-GTT GCT GTA 
GCC AAA TTC GTT GT-3’. 
 
4.8 MethylMinerTM analysis of cell lines LnCaP versus LnCaP-abl  
The MethylMiner™ Enrichment Kit was used for methylation analysis of LnCaP 
versus LnCaP-abl cell lines. This kit enables the enrichment and isolation of 
CpG methylated DNA only, by the use of the antibody against 5-methylcytosine 
(5mC). Afterwards specific gene targets of interest are analysed using RT-PCR 
method.  
4.8.1 MethylMinerTM Protocol 
The protocol was carried out as described in the handbook (Invitrogen life 
technologies handbook page 15-25). In our experimental setting 2µg DNA was 
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used for every sample. Accordingly, the protocol was performed in appropriate 
working steps based on the handbook. We analysed the cell lines LnCaP and 
LnCaP-abl. The methylated DNA (SssI treated) served as positive control.  
4.9 Protein Isolation  
For protein extraction from cells, 200µL HUNT extraction Buffer was used. The 
cell suspension was frozen in liquid nitrogen and thawed at 37°C, then again 
frozen and thawed on ice for 15 min. To remove the insoluble components, a 
centrifugation step was performed (4°C/13.200rpm). Supernatant was taken 
off and measured with NanoDrop 2000 (Thermo Scientific). 
4.10 Protein Analysis - Western Blot 
60µg of protein extract was loaded per lane on a SDS – Polyacrylamid Gel. 5% 
and 15% solution: 1.5M Tris pH 8.8; H2O; 30% Polyacrylamid; Sodium dodecyl 
sulphate - SDS; Ammonium Persulfate; Tetramethylethyleneediamine- 
TEMED). Equal amounts of 2xSDS gel loading dye were added to 60µg isolated 
protein sample and incubated at 95°C for 5 min. Separation was performed on 
a 5-15% SDS PAGE at 120V for 2hours or 20V for 16hours. Colorplus 
Prestained Protein Ladder broad range 10-230 kDa (New England BioLabs) was 
used as marker. Blotting the separated proteins to a Nitrocellulose Membrane 
(Whatman) was performed with wet blotter system and further visualized with 
Ponceau Red solution to check for equal amounts of loaded samples. The blot 
was then blocked in Blocking Solution for one hour. The primary antibodies 
(see Table 2) were diluted in blocking solution and incubated o/n on a shaker. 
The blot was washed three times with TBS-T and incubated with secondary 
antibodies (see Table 2) 1:10000 diluted in TBS-T for one hour at RT. The blot 
was washed again three times with TBS-T. Protein bands were visualized by 
using GE* Healthcare Amersham* ECL Plus Western Blotting Detection Reagent 
and analysed with LUMI Analyst (Roche).  
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5 Results 
5.1 Methylation analyses in cell lines and prostate carcinomas using 
COmbined Bisulphite Restriction Analysis – COBRA 
COBRA was performed in human prostate cancer cell lines PC-3, LNCaP and 
LNCaP-abl as well as in three different prostate cancer patient groups to 
determine the methylation status of candidate tumour suppressor genes 
(Table 4). For our experiment, SssI DNA from peripheral blood mononuclear 
cells (PBMCs) served as a positive control for methylation. Results were 
categorised in either unmethylated (U) or hypermethylated (M).  
Images of the restriction profiles for cell lines and patient samples are shown 
in Suppl.Fig.1 and 2. 
We chose a set of candidate genes known to be hypermethylated in different 
cancers for our analyses. APC and p14 were found unmethylated in all 
investigated cell lines. Interestingly, APC and p14 are the only targets found 
unmethylated in the hormone independent cell line PC-3, while the other seven 
remaining candidate gene loci DAPK-1, EDNRß, ESR-1, GSTP1, p16, RASSF1 
and WNT2 were detected as hypermethylated. In regard to our data, the more 
aggressive hormone insensitive PC-3 cells exhibited a higher methylation level 
compared to hormone-dependent cell line LNCaP. Interestingly, the in vitro 
generated hormone insensitive LNCaP-abl subline shows slightly elevated 
methylation frequencies compared to their parental cell line, indicating that 
epigenetic changes are involved in the transgression from hormone sensitivity 
to hormone insensitivity in PC. 
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Table 4| Summary of COBRA results of prostate cancer cell lines and patients. 
 
 
Next, we examined samples from patients, whose tumours were hormone-
dependent (n=8) (naive), samples from patients who had received hormone 
ablation therapy (n=8) (HAT) followed by prostatectomy and from patients 
with hormone-insensitive prostate cancer (n=7) (HI). The cystectomy DNA 
sample was used as control for healthy tissue.  
Our data show that HI patients display a higher methylation frequency for 4 of 
the 9 genes tested as compared to naive and HAT patients (Tab.4 and Fig.4). 
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Figure 1| COBRA results of patient samples – all targets: methylated gene targets. naive 
patients n=8; HAT patients n=8; HI patients n=7.  
 
 
Figure 1 shows a summary of the COBRA analyses comprising the naïve 
patient samples, those after hormone ablation therapy and those of hormone-
insensitive patients. Most of the genes tested showed similar methylation 
levels in the three groups. Elevated methylation levels were detected in 
EDNRß, GSTP1, p14 and WNT2 in HI patients compared to naive and HAT 
patients, while ESR-1 methylation seems to be more distinct in hormone-
dependent cancer stages. DAPK-1 and p16 showed low frequency of 
methylation in all patient groups. Because we obtained variable restriction 
patterns for the gene targets of DAPK-1 in naive and EDNRß in HAT patients, 
we could not interpret their methylation profiles. For this reason these data 
were designated as not determined (n.d.). 
Together, our data demonstrate a trend towards higher methylation in hormone 
insensitive cell lines and tumours as compared to hormone dependent 
samples. 
 
5.2 Chromatin Immunoprecipitation (ChIP) - H3K27me3 and 
recruitment of EZH2 at the WNT1 promoter in prostate cancer cell lines 
LNCaP and LNCaP-abl 
In our study, we used chromatin immunoprecipitation to analyse the presence 
of the histone modification H3K27me3 at the WNT1 promoter encoding a 
proto-oncogene in two related prostate cancer cell lines. In particular, ChIP and 
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subsequently quantitative PCR (qPCR) were performed in the LNCaP cell line 
and its subline LNCaP-abl. It was reported previously that WNT1 expression 
levels are higher in LNCaP cells compared to PC-3 cells (Thiele, Rauner et al. 
2011). The aim of this experiment was to find cell line specific histone 
modification patterns at the WNT1 locus due to the histone methyltransferase 
activity of EZH2. For this purpose, ChIP was performed with antibodies against 
the histone modification H3K27me3 as well as for the PRC2 subunit EZH2 
(Fig.2).  
 
 
Figure 2| EZH2 (A) and H3K27me3 (B) ChIP: (A) EZH2 is recruited to the WNT1 gene 
locus; (B) The H3K27me3 mark is present at the WNT1 promoter in LNCaP and 
LNCaP-abl cells: Chromatin Immunoprecipitation with LNCaP and LNCaP-abl cells was 
performed with 100µg chromatin and 10µg antibody against EZH2 and H3K27me3. The ChIP 
protocol was performed as described in materials and methods above. Results are displayed as 
fold enrichment compared to GAPDH. 
 
EZH2 is the major histone methyltransferase for the H3K27me3 modification. 
The performed EZH2 ChIP confirmed the recruitment of EZH2 to the WNT1 
gene locus in both cell lines (Fig.2A). Furthermore, a strong enrichment of 
trimethylation of H3K27 was detected in both LNCaP and LNCaP-abl cells 
(Fig.2B). These findings suggest the recruitment of EZH2 to the WNT1 locus 
and consequently imply epigenetic silencing due to the repressive H3K27me3 
mark. However, these results are in contrast to data which have shown that 
LNCaP cells express higher levels of WNT1 compared to PC-3 cells (Thiele, 
Rauner et al. 2011).  
Summarizing our data, we could show EZH2-mediated trimethylation of H3K27 
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in the human prostate cancer cell lines LNCaP and LNCaP-abl. These histone 
modifications might indicate epigenetic silencing or down-regulation of WNT1. 
Our findings showed no cell line specific difference in the recruitment of EZH2 
and the trimethylation of H3K27 at the WNT1 promoter. We suggest that this is 
due to the close relationship of LNCaP and LNCaP-abl cells. 
 
5.3 CpG island methylation analysis in LNCaP and LNCaP-abl cell lines 
with MethylMinerTM 
The MethylMiner™ enrichment kit was used for LNCaP versus LNCaP-abl cell 
lines for methylation analysis. This kit enables the enrichment and isolation of 
methylated DNA by the use of the 5-methylcytosine binding protein MBD2. By 
the use of specific primers we analysed several genes including HIST, UBE2B, 
H19, SHP2, WNT2 and DAPK-1. The aim of this analysis was to find specific 
methylation changes or differences within these two cell lines in prospect to 
carry out genome-wide methylation analysis. The UBE2B gene is encoding the 
human ubiquitin-conjugating enzyme E2B. The modification of proteins with 
ubiquitin is an important cellular mechanism for targeting abnormal or short-
lived proteins for degradation. SHP2 is a protein tyrosine phosphatase that 
regulates cellular processes including oncogenic transformations. DAPK-1 and 
WNT2 showed slightly enriched methylation in both cell lines compared to the 
positive control as determined by COBRA analysis.  
As expected, we were able to precipitate known methylated regions within the 
WNT2, SHP2 and DAPK1 promoter regions, whereas no precipitation was 
obtained for HIST and UBE2B, two non-methylated control regions within the 
histone H3 and UBE2B promoter, respectively (Fig.3). The imprinted gene 
H19, which was expected to display 50% methylation, was also not 
precipitated. However, genome-wide methylation analyses in LNCaP cells 
available from the ENCODE consortium (ENCODE 2011) confirmed our results 
and did not show methylation of this region either (data were produced by the 
Dr. Richard Myers Lab and the Dr. Devin Absher lab at the HudsonAlpha 
Institute for Biotechnology).  
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Thus, we conclude, that these assays would be suitable for genome-wide 
analyses of hypermethylated DNA regions. 
 
 
Figure 3| MethylMiner assay: Promoter methylation at promoter sites of WNT2, SHP2 
and DAPK in LNCaP and LNCaP-abl cells. MeMiner assay performed on LNCaP and LNCaP-
abl cells displays enrichment of methylated gene regions compared to control regions. SssI 
treated DNA was used as positive control. 
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5.4 Expression of enzymes involved in epigenetic processes 
Protein analysis was performed in human prostate cancer cell lines LNCaP, 
LNCaP-abl, PC-3 and DU145 to compare expression levels in hormone-
dependent and hormone-independent cells. 
 
 
Figure 4| Expression of enzymes involved in epigenetic processes in human prostate 
cell lines. LNCaP, LNCaP-abl (abl), PC-3 and DU145 protein extracts were probed with 
antibodies against DNMT1 (left) and EZH2 (right). LNCaP and abl cells displayed reduced 
DNMT1 protein levels, whereas PC-3 and DU145 cell lines showed increased levels. 
Furthermore, the EZH2 level was distinctively lower in PC-3 cells and elevated in LNCaP cells. 
Per lane 60µg protein extract were loaded onto a 5-15% SDS-Gel. ß-actin was used as loading 
control. 
 
 
Interestingly, PC-3 and DU145 exhibited elevated protein levels of DNMT1 
compared to the LNCaP cell lines. Vice versa, EZH2 was increased in LNCaP 
and LNCaP-abl cells compared to PC-3 cells. DU145 cells were found slightly 
decreased in EZH2 expression at protein levels compared to LNCaP and LNCaP-
abl (Fig.4). 
These findings contribute to our hypothesis of an existing difference between 
hormone-dependent and hormone-independent cancer types based on 
epigenetic alterations, but do not correlate to previous findings where elevated 
EZH2 levels are linked to disease progression (Varambally, Dhanasekaran et al. 
2002). 
 
5.5 Immunohistochemical (IHC) staining of a tissue array from 
patient samples with different prostate cancer stages 
Immunohistochemical staining was performed to determine putative 
differences in histone modifications or levels of epigenetic enzymes between 
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prostatectomy tissue samples of three different prostate cancer groups. These 
tissues were compared to normal tissue obtained from a cystectomy. We 
expected to detect specific modification changes during cancer progression. For 
this purpose, we stratified staining into three categories: positive (++), 
moderate (+) or negative staining (-) (see also Suppl.Fig.3). 
As mentioned before, aberrant DNMT1 expression has been correlated to 
androgen independence in prostate cancer (Chen, Chen et al. 2010), as well as 
the increase of DNMT3a (Gravina, Marampon et al. 2011). In our current study, 
we observed the most prominent nuclear DNMT1 staining in HI patients (Fig.6, 
Fig.9 and Tab.5) however, unspecific background staining might interfere with 
this observation. We also detected stronger staining for DNMT3a in HI cancer 
samples compared to moderate levels in naive patients (Fig.6, Fig. and 
Tab.5). DNMT3a was not detected in the cystectomy tissue and the majority of 
HAT patients (Fig.6, Fig. and Tab.5). BMI-1 was found positively expressed in 
HI and naive cancerous tissues (Fig.6, Fig.9 and Tab.5). CTCF (Fig.8), 
H3K27me3 and H3K4me3 (Fig.5 and Tab.5) (Fig.7 and Tab.5) were detected 
in all patients at comparable levels. Concerning HDAC protein levels, HDAC1 
expression was detected in all samples analysed with the most prominent 
staining in the cystectomy (Fig.7 and Tab.5). Further, HDAC2 expression was 
found in all three cancer groups, whereas HI tissue samples showed the 
highest staining results compared to naive and HAT patients (Fig.7, Fig.9 and 
Tab.5). A moderate HDAC3 staining was detected in naive, HI patients and the 
cystectomy sample, but no staining was found in HAT patients (Fig.7 and 
Tab.5). However, the cystectomy sample showed strong expression levels of 
HDACs compared to probed tumour samples. 
Although differences in protein expression levels were detected, it has to be 
pointed out that for statistically significant results a larger sample number of 
each patient cohort has to be analysed. For a summary of all patients see 
Table 5. 
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Figure 5| Tissue Array: IHC staining with ABs against H3K27me3 and H3K4.  
Cystectomy; naive tumours; HAT = tumours after hormone ablation therapy; HI = Hormone 
Insensitive tumours. 
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Figure 6| Tissue Array: IHC staining with ABs against DNMT1, DNMTt3a and BMI-1. 
Cystectomy; naive tumours; HAT = tumours after hormone ablation therapy; HI = Hormone 
Insensitive tumours. 
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Figure 7| Tissue Array: IHC staining with ABs against HDAC1/2/3. 
Cystectomy; naive tumours; HAT = tumours after hormone ablation therapy; HI = Hormone 
Insensitive tumours. 
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Figure 8| Tissue Array: IHC staining with ABs against CTCF and Ki67. 
Cystectomy; naive tumours; HAT = tumours after hormone ablation therapy; HI = Hormone 
Insensitive tumours. 
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Figure 9| BMI-1, DNMT1 and DNMT3a IHC staining ratio among patient groups. 
 
 
 
47 
 
 
Table 5| IHC overview and evaluation of naive, HAT and HI patient samples. 
 
Table 5 gives an overview of all evaluated patient samples. Tissue samples 
were classified according to moderate (+), positive (++) and negative (-) 
staining.  
 
In conclusion, elevated expression of DNMT1, DNMT3a and HDAC2 in HI cancer 
samples compared to naïve and HAT patients implies a tendency towards 
different regulations of certain epigenetic enzymes between hormone-sensitive 
and insensitive cancer stages. Especially the observations of increased DNMT1 
and DNMT3a levels are supported by previous studies for androgen 
independency in prostate cancer (Chen, Chen et al. 2010; Gravina, Marampon 
et al. 2011). Nevertheless, based on the small sample number of our study, a 
distinct conclusion is difficult to make. 
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6 Discussion  
Our focus in this study was to find differences between hormone-dependent 
and independent cancer types, which are based on epigenetic alterations. This 
was tested in hormone-sensitive and insensitive patient samples and cell lines. 
One aim was to isolate a group of genes, which are specifically 
hypermethylated in certain stages of prostate cancer to identify differences 
between hormone sensitive and insensitive cancer groups. 
In this study, we detected WNT2, EDNRß, RASSF1a, p14 and GSTP1 
hypermethylated in hormone-insensitive cancer tissues (Tab.4 and Fig.1). 
GSTP1, which is known to be methylated in 90% of PC cases and a potential 
biomarker in PC diagnosis, was also found to be hypermethylated in all cell 
lines in our study (Lee, Morton et al. 1994; Jeronimo, Usadel et al. 2001; 
Nakayama, Bennett et al. 2003). 
Also, EDNRß methylation has been shown to correlate with disease progression 
before (Bastian, Palapattu et al. 2008). Interestingly, hypermethylation was 
exclusively found for the ESR-1 loci in hormone-sensitive cancer tissues. 
Previously studies showed that down-regulation of ESR-1 was linked to cancer 
metastasis and its methylation is age-dependent (Li, Shiina et al. 2004). 
However, ESR-1 methylation was observed to be differentially methylated in 
PCs (Yegnasubramanian, Kowalski et al. 2004; Kwabi-Addo, Chung et al. 2007; 
Vasiljevic, Wu et al. 2011). Interestingly, we found no methylation in HI patient 
samples (Tab.4 and Fig.1). Normally, prostate epithelial cells are free of 
methylation in the ESR-1 promoter region. In cancer tissue, estrogens can 
affect prostatic cancerogenesis and neoplastic progression through an estrogen 
receptor-mediated process in human prostate tissue (Bonkhoff, Fixemer et al. 
1999). Reduced expression of the ESR-1 gene has been shown in PC, 
particularly in hormone refractory tumours (Latil, Bieche et al. 2001). 
Furthermore, WNT2 expression has been reported to be reduced in prostate 
cancer (Wissmann, Wild et al. 2003), which is in line with our analysis 
revealing a variable methylation pattern at the WNT2 promoter region (Tab.4, 
Fig.1 and Fig.3). APC hypermethylation has been reported in the context of 
prostate cancer (Kang, Lee et al. 2004). We confirmed APC to be 
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hypermethylated in patient samples, although in HI patients a majority was 
not methylated (Tab.4 and Fig.1). Jeronimo et al. pointed out that the 
occurrence of methylated GSTP1 together with the APC gene facilitates a more 
sensitive detection of prostate cancer (Jeronimo, Henrique et al. 2004). 
Oncogenic potential was reported by repression of the tumour suppressor 
genes p14 and p16 (Lowe and Sherr 2003). Interestingly, the majority of 
patient cancer tissue in our study showed hypermethylation at the p14 gene 
locus and weak to no methylation at the p16 promoter (Tab.4 and Fig.1). No 
methylation was detected for p14 in the three cell lines tested and only PC-3 
cells showed p16 specific methylation (Tab.4 and Fig.1), indicating that the 
CDKN2A locus might not be a common target of DNA hypermethylation in 
prostate cancer. 
Unexpectedly, ESR-1, p14, RASSF1a and WNT2 were methylated in the normal 
control sample (Tab.4). This sample was isolated from a patient with bladder 
cancer, who had undergone cystectomy. Frequently, such patients also display 
early stages of prostate cancer, which might explain our findings. 
Consequently, for further investigations a suitable negative control should be 
used. 
Notably, in the course of our studies, we observed different restriction patterns 
in COBRA analysis for patients and cell lines in contrast to the positive SssI 
control sample. For example, a distinct methylation-restriction profile was seen 
at DAPK-1 and RASSF1a especially in PC-3 (Suppl.Fig.1). We assume that 
there must be a difference regarding the degree of DNA methylation, which is 
indicated by either strong and weak restriction bands or the loss of specific 
bands when compared to the positive control. 
Another interesting finding in this study was the up-regulation of DNMT3a in HI 
patients (Fig.6, Fig.9 and Tab.5). DNMT1 showed moderate nuclear staining 
in a majority of hormone insensitive patients (Fig.6, Fig.9 and Tab.5), which 
is in line with previous studies (Gravina, Marampon et al. 2011). It was 
reported that during hormone ablation therapy DNMT activity is increased 
through epigenetic mechanisms, which favors the development of a hormone-
resistant phenotype (Gravina, Marampon et al. 2011). It was also observed in 
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previous studies that increased EZH2 levels are correlated with enhanced 
H3K27 trimethylation (Cao, Wang et al. 2002). Unfortunately, we were not able 
to detect EZH2 by IHC-staining on our samples, which might be due to the lack 
of a specific antibody, however we could confirm higher EZH2 expression levels 
in cell lines using Western blot analysis (Fig.4). 
We confirmed the proto-oncogene WNT1 as a target gene for H3K27 
trimethylation by EZH2 in prostate cancer cell lines LNCaP and LNCaP-abl, 
using ChIP analysis (Fig.2). The down-regulation and inhibition of WNT1 was 
reported previously to induce apoptosis in colorectal cancer cells (He, Reguart 
et al. 2005) and is likely to have a function as a tumour suppressor. 
Unfortunately, our aim to find differences between these related cell lines could 
was not met. Nevertheless, it would be interesting to include an additional 
hormone-insensitive cell line such as PC-3 for future studies. The LNCaP-abl 
cells have been generated in vitro and might not completely reflect the in vivo 
phenotype of a hormone insensitive prostate cancer cell line. 
MethylMiner assays in LNCaP and LNCaP-abl cell lines showed methylation at 
the WNT2, SHP2 and DAPK-1 gene loci in both cell lines (Fig.3).These findings 
corresponded with methylation data provided by the ENCODE consortium. 
SHP2 was identified earlier to favour the risk of gastric cancer and its down-
regulation has been shown to be due to DNA methylation (Katoh 2007). 
Additionally, we found elevated methylation at the DAPK-1 gene locus (Fig.3), 
which did not correspond to our COBRA data (Tab.4). However, available 
ENCODE data confirmed our results, both for the COBRA and the MethylMiner 
assays, since we did examine different loci within the DAPK-1 gene, which 
displayed different methylation levels.  
In conclusion, our results indicate that there are specific epigenetic alterations 
between hormone-sensitive and insensitive prostate carcinomas and provide 
the grounds for further genome-wide experiments. We expect that such 
analyses will help to classify prostate cancers by epigenetic molecular 
biomarkers and might be useful tools for diagnosis or prognosis of prostate 
cancer in clinical route in the future. 
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8 Abbreviations 
ABs   Antibodies 
AP-1   Activator Protein 1 
APC   Adenomatous polyposis coli 
BMI-1  B lymphoma Mo-MLV insertion region 1 homologue 
cJun   Jun proto-oncogene; AP-1 transcription factor family 
CTCF   CCCTC-binding factor 
DAPK-1  Death Associated Protein Kinase 1 
DNMT  DNA methyltransferase 
DNMT1  DNA (cytosine-5)-methyltransferase 1 
DNMT3a/3b DNA (cytosine-5)-methyltransferase 3 alpha/beta 
EDNRB  Endothelin receptor type B  
ESR-1  Estrogen Receptor alpha 
EZH2   Enhancer of Zeste homologue 2 
FFPE   Formalin fixed paraffin embedded 
GSTP1  Glutathione S-transferase P 1  
HAT   Hormone ablation therapy 
HDAC  Histone deacetylase 
HI   Hormone-insensitive 
HMT   Histone methyltransferase 
H3K27me3  trimethylation of Histone 3 at Lysine 27 
H3K4   Histone 3 Lysine 4 
JunB   Jun proto-oncogene; AP-1 transcription factor family 
Ki-67   Antigen Ki-67 
MYT1pd  Myelin-transcription-factor 1  
MYT1prox  Myelin-transcription-factor 1 proximal 
PBMC   peripheral blood mononuclear cells  
PC   Prostate Cancer 
PcG   Polycomb Group Protein 
p14 Cyclin-dependent kinase inhibitor 2A - alternative reading 
frame of CDK2NA 
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p16   Cyclin-dependent kinase inhibitor 2A - CDK2NA 
PRC2   Polycomb Repressive Complex 2 
PSA   Prostate Specific Antigen  
RASSF1  Ras association domain-containing protein 1  
SAM   S-Adenosylmethionine  
SHP2 (PTPN11) SH2 domain-containing protein tyrosine phosphatase  
SNPs   Single nucleotide polymorphism 
TMA   Tissue Micro-array 
TF   Transcription Factor 
UBE2B  Ubiquitin-conjugating enzyme (E2B)  
WNT1  Wingless-type MMTV integration site family member 1  
WNT2  Wingless-type MMTV integration site family member 2 
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9 Supplementary Figures 
 
Supp.Figures 1| COBRA restriction: Cell lines 
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Supp.Figures 2| COBRA restiction: naive ; HAT ; HI patients. 
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Supp.Figures 3| IHC staining intensity evaluation: Example of DNMT3a. 
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